May 24, 2017 —BOSTON, MA., and STOCKHOLM, SWEDEN, May 23, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patient was enrolled in the Phase Ib/II

March 22, 2017 —BOSTON, MA., and STOCKHOLM, SWEDEN, March 22, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced a collaboration with Memorial Sloan Kettering Cancer

January 7, 2017 — BOSTON, MA. and STOCKHOLM, SWEDEN, January 5, 2017  – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.

October 22, 2016 —Dr. Mikael von Euler will present data from Aprea Therapeutics’ Phase Ib study in high-grade serous ovarian cancer at the  7th International Mutant p53 Workshop in Melbourne, Australia . This oral presentation is scheduled for 11:35 AM on Friday October 28, 2016 as part of Session

October 10, 2016 — BOSTON, MA., and STOCKHOLM, SWEDEN, October 10, 2016  – Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the

October 10, 2016 — BOSTON, MA. and STOCKHOLM, SWEDEN, October 10, 2016  – Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that it enrolled the first patients in the

June 16, 2016 — Boston, MA, USA and Stockholm, Sweden, June 16, 2016  – Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.

June 6, 2016 — June 6, 2016, Stockholm, Sweden –  Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial in

March 9, 2016 — One of Largest Financings Ever for a Private Scandinavian Biotech Company Participation by Top-Tier International Investors Funds to Support Next Stage of Clinical Development, including Phase II Trial in Ovarian Cancer, for APR-246, First-in-Class Anticancer Compound Reactivating